Alzheimer's disease research, amyloid plaques, tau tangles, and cognitive decline
295 articles
A new tool that boosts mitochondrial activity in neurons restored memory in dementia mice, suggesting energy failure drives Alzheimer's symptoms.
27-Hydroxycholesterol triggers microglial senescence through iron dysregulation, and the iron chelator deferoxamine reverses the damage.
Cannabis use is surging among adults over 65, but Stanford Medicine specialists say today's potent marijuana carries serious, underestimated health risks.
Applied Cognition tests a wearable device that tracks glymphatic function overnight, comparing it to MRI, EEG, and blood biomarkers.
A Phase 1/2 trial tests whether dexmedetomidine can enhance the brain's glymphatic system to clear amyloid and tau during sleep.
Specific AQP4 genetic variants alter glymphatic drainage efficiency, directly influencing motor symptom severity and progression in early Parkinson's disease.
A landmark RCT tests whether hearing aids can protect brain health in 977 older adults over 3 years.
A landmark multicohort proteomics study reveals how APOE2 and APOE4 shape Alzheimer's risk through entirely distinct molecular mechanisms.
A completed trial tests EGCG combined with diet, exercise, and cognitive training to slow decline in ApoE4 carriers with early warning signs.
A master autophagy regulator drops with age and in AD patients — restoring it in mice clears amyloid, reduces tau, and rescues cognition.
Scientists used stem cell-derived vesicles to deliver light-activated gene therapy to the brain without surgery, reversing cognitive decline in Alzheimer's mice.
A bibliometric analysis of 595 papers maps how glymphatic-Alzheimer's research has grown exponentially, pinpointing AQP4, sleep, and DTI-ALPS imaging as the hottest frontiers.
